Molecular Partners Ag (MOLN) Liabilities and Shareholders Equity (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Liabilities and Shareholders Equity of $111939.7 for Q1 2026, down 100.0% year-over-year from $156.9 billion in Q1 2025, and up 87521.82% quarter-over-quarter from $127.75 in Q4 2025.
Molecular Partners Ag (MOLN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $111939.7 the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 100.0% year-over-year to $111939.7; the TTM figure through Mar 2026 stood at $252417.3 (down 100.0% YoY), while the FY2025 annual figure was $127.75, down 100.0% from the prior year.
- Liabilities and Shareholders Equity climbed to $111939.7 in Q1 2026 per MOLN's latest filing, from $127.75 in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $337.7 billion in Q1 2022 and bottomed at $127.75 in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $99.4 billion across 5 years, with a median of $272.2 million in 2022.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 51.57% — and 2025, when it sank 100.0%.
- Molecular Partners Ag's Liabilities and Shareholders Equity stood at $272.2 million in 2022, then fell by 17.86% to $223.6 million in 2023, then dropped by 19.07% to $181.0 million in 2024, then tumbled by 100.0% to $127.75 in 2025, then surged by 87521.82% to $111939.7 in 2026.
- Business Quant data shows MOLN's Liabilities and Shareholders Equity at $111939.7 in Q1 2026, $127.75 in Q4 2025, and $140199.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 19.82 Bn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 111,939.68 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111,939.68 |
| Dec 31, 2025 | 127.75 |
| Sep 30, 2025 | 140,199.78 |
| Jun 30, 2025 | 150.08 |
| Mar 31, 2025 | 156.94 Bn |
| Dec 31, 2024 | 180.96 Mn |
| Sep 30, 2024 | 177.99 Bn |
| Jun 30, 2024 | 188.67 Mn |
| Mar 31, 2024 | 212.64 Bn |
| Dec 31, 2023 | 223.61 Mn |
| Sep 30, 2023 | 246.94 Bn |
| Jun 30, 2023 | 256.35 Mn |
| Mar 31, 2023 | 264.38 Bn |
| Dec 31, 2022 | 272.23 Mn |
| Sep 30, 2022 | 291.13 Bn |
| Jun 30, 2022 | 310.75 Mn |
| Mar 31, 2022 | 337.67 Bn |
| Dec 31, 2021 | 187.26 Mn |
| Sep 30, 2021 | 192.08 Bn |
| Dec 31, 2020 | 207.46 Mn |